Scientists have discovered that montelukast, a widely used asthma medication, could help improve cancer immunotherapy responses in hard-to-treat cancers like triple-negative breast cancer.
A new study published in Nature Cancer found that tumors may hijack immune cells called neutrophils through a receptor known as CysLTR1, helping cancers evade the immune system. Researchers showed that blocking this receptor with montelukast slowed tumor growth and improved survival in preclinical models. The findings raise hopes for repurposing an existing, FDA-approved drug to make resistant cancers more responsive to treatment. However, experts stress that clinical trials are still needed before it can become part of routine cancer care.
Read more at LiveScience
